---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-26-000053"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2026-06-18T11:00:03+00:00"
generated_at: "2026-06-18T11:05:24.119323+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Novocure Phase 3 TRIDENT trial fails to show survival benefit for early TTFields in GBM

## Summary
- Median OS 17.7 mo (Early Start) vs 17.5 mo (Maintenance Start); HR 0.953, p=0.519.
- 981 patients enrolled; 25% did not initiate maintenance phase across both arms.
- 1-/2-/3-year survival rates: Early Start 70.9%/33.9%/22.5%; Maintenance 72.0%/31.6%/18.4%.
- No new safety signals; TTFields with chemoradiation was well-tolerated.
- Results accepted for presentation at ASTRO 2026 Annual Meeting.

## SEC filing metadata
- accession: 0001645113-26-000053
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2026-06-18T11:00:03+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000053/0001645113-26-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000053/nvcr-20260618.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-26-000053
- JSON: https://secwatch.observer/filing/0001645113-26-000053.json
- Plain text: https://secwatch.observer/filing/0001645113-26-000053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.